PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34273250-0	2021	Prediction of the drug-drug interaction potential of the alpha-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.	erdafitinib	129-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94	
34273250-3	2021	This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug-drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors, and CYP3A4/CYP2C9 inducers on erdafitinib PK in cancer patients exhibiting higher AGP levels and in population with different CYP2C9 genotypes.	erdafitinib	80-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-153	
34273250-3	2021	This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug-drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors, and CYP3A4/CYP2C9 inducers on erdafitinib PK in cancer patients exhibiting higher AGP levels and in population with different CYP2C9 genotypes.	erdafitinib	80-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	181-187	
34273250-3	2021	This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug-drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors, and CYP3A4/CYP2C9 inducers on erdafitinib PK in cancer patients exhibiting higher AGP levels and in population with different CYP2C9 genotypes.	erdafitinib	207-218	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	181-187	
34273250-4	2021	Erdafitinib"s DDI potential as perpetrator for transporter inhibition and for time-dependent inhibition and/or induction of CYP3A was also evaluated.	erdafitinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-129	
31673875-12	2020	CONCLUSION: Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.	erdafitinib	138-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101	
34189909-0	2021	Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.	erdafitinib	111-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-59	
35153194-1	2022	We recently established the mechanism-based inactivation (MBI) of cytochrome P450 3A (CYP3A) by the fibroblast growth factor receptor (FGFR) inhibitors erdafitinib and infigratinib.	erdafitinib	152-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-84	
35153194-1	2022	We recently established the mechanism-based inactivation (MBI) of cytochrome P450 3A (CYP3A) by the fibroblast growth factor receptor (FGFR) inhibitors erdafitinib and infigratinib.	erdafitinib	152-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-91	
31673875-2	2020	The aim of this phase 1 study was to assess the pharmacokinetics and safety of erdafitinib in healthy participants when coadministered with fluconazole (moderate CYP2C9 and CYP3A inhibitor), and itraconazole (a strong CYP3A4 and P-glycoprotein inhibitor).	erdafitinib	79-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-178	
31673875-12	2020	CONCLUSION: Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.	erdafitinib	138-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	291-297	
31673875-2	2020	The aim of this phase 1 study was to assess the pharmacokinetics and safety of erdafitinib in healthy participants when coadministered with fluconazole (moderate CYP2C9 and CYP3A inhibitor), and itraconazole (a strong CYP3A4 and P-glycoprotein inhibitor).	erdafitinib	79-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	218-224	
31673875-12	2020	CONCLUSION: Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.	erdafitinib	189-200	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101